Seven-week continuous-infusion XXXX concurrent with radiation therapy for locally advanced non-small cell lung and @entity135 .

@entity1 @entity135 @entity137 @entity5 @entity1149 @entity1311 @entity213
The goal of these National Cancer Institute-sponsored phase I trials is to determine the feasibility, @entity137 , and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous @entity1311 combined with standard, curative-intent thoracic radiation therapy (XRT) for previously untreated, locally advanced @entity1149 and @entity135 ( @entity213 ). Eligible @entity1 have locally advanced (T4NXM0 or TXN2-3M0) @entity1149 ineligible for potentially curative surgical resection or locally advanced @entity213 with an expected 5-year survival rate of less than 25%, as well as a good performance status, adequate hematologic, hepatic, and renal function, and no distant metastases. @entity1149 @entity1 receive a total @entity5 dose of 64.8 Gy megavoltage XRT in 7 weeks at 1.8 Gy once daily, 5 d/wk. @entity1 with @entity213 receive 70 Gy megavoltage XRT in 7 weeks at 2 Gy once daily, 5 d/wk. @entity1311 is delivered by continuous intravenous infusion starting 48 hours before XRT and continuing for its duration. The dose of @entity1311 is escalated in cohorts of three @entity1 in a standard phase I design. To date, 49 @entity1 have been entered on both studies and 43 are evaluable for @entity137 . @entity1311 dose is currently at the 17 mg/m2/d dose level, with no dose-limiting @entity137 thus far. Clinical outcomes suggest significant activity for this combination. This therapy is feasible and has been well-tolerated through current dose levels. Dose escalation is ongoing.
